Study study type PathologyT1T0Patientssample sizesROB Results

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

versus Standard of Care (SoC)
durvalumab plus tremelimumab
MYSTIC (DT ; all population), 2020
  NCT02453282
RCTmNSCLC - L1 - all populationdurvalumab and tremelimumabplatinum-based doublet chemotherapyfirst-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%372 / 372some concern
inconclusive
    no statistically significant result
nivolumab plus ipilimumab plus SoC
CheckMate 9LA, 2021
  NCT03215706
RCTmNSCLC - L1 - all populationnivo plus ipi and chemo (2 cycle)chemotherapy platine combinationpatient treated as First Line Therapy in squamous or non-squamous stage IV or recurrentNSCLC361 / 358some concern
conclusif
  • demonstrated 31 % decrease in deaths (OS) (PE)
  • demonstrated 30 % decrease in progression or deaths (PFS) (PE)
  • suggested 34 % decrease in deaths (OS) (extension)
  • suggested 32 % decrease in PFS (extension)
  • more...

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus pembrolizumab plus placebo
pembrolizumab plus ipilimumab
KEYNOTE-598, 2020
  NCT03302234
RCTmNSCLC - L1 - PDL1 positivepembrolizumab plus ipilimumabplacebo plus pembrolizumabas first-line treatment of patients with metastatic NSCLC whose tumors express PD-L1 with a tumor proportion score (TPS) ≥50% and no EGFR or ALK aberrations284 / 284low
inconclusive
  • inconclusive 8 % increase in deaths (OS) (PE)
  • inconclusive 6 % increase in progression or deaths (PFS) (PE)
versus pemetrexed plus platin
nivolumab plus ipilimumab
CheckMate 227 (NI vs C ; PDL1>1%), 2018
  NCT02477826
RCTmNSCLC - L1 - PDL1 positivenivolumab plus ipilimumabplatinium chemotherapypatients with histologically confirmed squamous or nonsquamous stage IV or recurrent NSCLC who had received no previous systemic anticancer therapy and PDL1>1%396 / 397some concern
conclusif
  • demonstrated 21 % decrease in deaths (OS) (PE)
  • suggested 18 % decrease in progression or deaths (PFS)
versus Standard of Care (SoC)
durvalumab plus tremelimumab
MYSTIC (DT ; PDL1>25%), 2020
  NCT02453282
RCTmNSCLC - L1 - PDL1 positivedurvalumab and tremelimumabplatinum-based doublet chemotherapyfirst-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%163 / 162some concern
inconclusive
  • inconclusive 15 % decrease in deaths (OS) (PE)
  • inconclusive 5 % increase in progression or deaths (PFS) (PE)

mNSCLC - L1 - TMB>10Mb metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - TMB10Mb

versus pemetrexed plus platin
nivolumab plus ipilimumab
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018
  NCT02477826
RCTmNSCLC - L1 - TMB>10Mbnivolumab plus ipilimumabplatinium chemotherapypatients with histologically confirmed squamous or nonsquamous stage IV or recurrent NSCLC who had received no previous systemic anticancer therapy and TMB > 10mut/Mb139 / 160some concern
conclusif
  • demonstrated 42 % decrease in progression or deaths (PFS) (PE)